Jeffrey Crowley

4.5k total citations
64 papers, 1.9k citations indexed

About

Jeffrey Crowley is a scholar working on Immunology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Jeffrey Crowley has authored 64 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Immunology, 23 papers in Dermatology and 11 papers in Pathology and Forensic Medicine. Recurrent topics in Jeffrey Crowley's work include Psoriasis: Treatment and Pathogenesis (42 papers), Dermatology and Skin Diseases (19 papers) and Autoimmune Bullous Skin Diseases (11 papers). Jeffrey Crowley is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (42 papers), Dermatology and Skin Diseases (19 papers) and Autoimmune Bullous Skin Diseases (11 papers). Jeffrey Crowley collaborates with scholars based in United States, Canada and Germany. Jeffrey Crowley's co-authors include Melinda Gooderham, Kim Papp, Jennifer Clay Cather, Paul S. Yamauchi, Bruce Strober, Diamant Thaçi, Francisco J. Blanco, Joana Gonçalves, C. Birbara and Robert M. Day and has published in prestigious journals such as The Lancet, Circulation and Annals of the Rheumatic Diseases.

In The Last Decade

Jeffrey Crowley

62 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey Crowley United States	24	1.5k	866	407	312	250	64	1.9k
Ming-Chun Hsu United States	9	1.5k 1.0×	824 1.0×	323 0.8×	281 0.9×	232 0.9×	14	1.7k
Thomas Salko United States	5	1.3k 0.9×	720 0.8×	333 0.8×	244 0.8×	212 0.8×	5	1.6k
Zenas Z N Yiu United Kingdom	21	1.2k 0.8×	898 1.0×	308 0.8×	198 0.6×	127 0.5×	72	1.8k
Pierre‐Dominique Ghislain Belgium	17	685 0.5×	625 0.7×	420 1.0×	342 1.1×	149 0.6×	36	1.5k
Yaung‐Kaung Shen United States	21	2.6k 1.8×	1.4k 1.6×	971 2.4×	346 1.1×	673 2.7×	37	3.0k
Yin You United States	17	1.0k 0.7×	478 0.6×	341 0.8×	132 0.4×	216 0.9×	34	1.2k
Siew Eng Choon Malaysia	20	1.1k 0.7×	718 0.8×	233 0.6×	319 1.0×	81 0.3×	52	1.5k
Scott Baumgartner United States	20	769 0.5×	350 0.4×	688 1.7×	271 0.9×	176 0.7×	52	2.0k
P. de la Cueva Spain	22	904 0.6×	554 0.6×	188 0.5×	124 0.4×	84 0.3×	107	1.2k
Kavitha Goyal United States	12	828 0.6×	389 0.4×	204 0.5×	130 0.4×	118 0.5×	22	1.0k

Countries citing papers authored by Jeffrey Crowley

Since Specialization

Citations

This map shows the geographic impact of Jeffrey Crowley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Crowley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Crowley more than expected).

Fields of papers citing papers by Jeffrey Crowley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Crowley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Crowley. The network helps show where Jeffrey Crowley may publish in the future.

Co-authorship network of co-authors of Jeffrey Crowley

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Crowley. A scholar is included among the top collaborators of Jeffrey Crowley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Crowley. Jeffrey Crowley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Peyrin‐Biroulet, Laurent, J F Colombel, Geert D’Haens, et al.. (2024). DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial. Journal of Crohn s and Colitis. 18(Supplement_1). i104–i105. 2 indexed citations

Ferrante, Marc, Remo Panaccione, Jean‐Frédéric Colombel, et al.. (2024). DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension. Journal of Crohn s and Colitis. 18(Supplement_1). i167–i169. 4 indexed citations

Langley, Richard G., Nehal N. Mehta, Jeffrey Crowley, et al.. (2023). 43250 Efficacy of Apremilast in Patients With Moderate-to-Severe Plaque Psoriasis Across Weight and BMI Subgroups: Analysis From ESTEEM 1 and ESTEEM 2. Journal of the American Academy of Dermatology. 89(3). AB158–AB158. 3 indexed citations

Crowley, Jeffrey, Chih-ho Hong, Melinda Gooderham, et al.. (2023). 44102 Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments. Journal of the American Academy of Dermatology. 89(3). AB82–AB82. 1 indexed citations

Blauvelt, Andrew, Diamant Thaçi, Kim Papp, et al.. (2023). Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. British Journal of Dermatology. 189(1). 132–134. 8 indexed citations

Augustin, Matthias, Richard G. Langley, Richard B. Warren, et al.. (2023). 42664 Itching in patients with moderate to severe plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and patient-reported symptoms in the BE RADIANT phase 3b trial. Journal of the American Academy of Dermatology. 89(3). AB184–AB184. 1 indexed citations

Crowley, Jeffrey, Richard G. Langley, Kenneth B. Gordon, et al.. (2022). Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatology and Therapy. 12(2). 561–575. 10 indexed citations

Blauvelt, Andrew, C. Leonardi, Boni E. Elewski, et al.. (2020). A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*. British Journal of Dermatology. 184(6). 1047–1058. 73 indexed citations

Reich, Kristian, Melinda Gooderham, Diamant Thaçi, et al.. (2019). Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. The Lancet. 394(10198). 576–586. 219 indexed citations

10.

Elewski, Boni E., Martin M. Okun, Kim Papp, et al.. (2017). Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. Journal of the American Academy of Dermatology. 78(1). 90–99.e1. 68 indexed citations

11.

Edwards, Christopher J, Francisco J. Blanco, Jeffrey Crowley, et al.. (2016). Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3). Annals of the Rheumatic Diseases. 75(6). 1065–1073. 215 indexed citations

12.

Rich, Phoebe, Melinda Gooderham, H. Bachelez, et al.. (2015). Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). Journal of the American Academy of Dermatology. 74(1). 134–142. 125 indexed citations

13.

Strober, Bruce, Jennifer Clay Cather, David Cohen, et al.. (2012). A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatology and Therapy. 2(1). 2–2. 10 indexed citations

14.

Strober, Bruce, Jennifer Clay Cather, David Cohen, et al.. (2012). A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatology and Therapy. 2(1). 1–1. 24 indexed citations

15.

Papp, Kim, Jeffrey Crowley, J.‐P. Ortonne, et al.. (2010). Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy. British Journal of Dermatology. 164(2). 434–441. 92 indexed citations

16.

Crowley, Jeffrey, et al.. (1997). Blastomycosis-like pyoderma in a man with AIDS. Journal of the American Academy of Dermatology. 36(4). 633–664. 9 indexed citations

17.

Crowley, Jeffrey & Youn H. Kim. (1995). Cutaneous gnathostomiasis. Journal of the American Academy of Dermatology. 33(5). 825–828. 8 indexed citations

18.

Crowley, Jeffrey & Thomas A. Raffin. (1991). Tumor Necrosis Factor-induced Protein Phosphorylation in Human Neutrophils. American Journal of Respiratory Cell and Molecular Biology. 5(3). 284–291. 2 indexed citations

19.

Zheng, Hui, Jeffrey Crowley, Jane C. Chan, & Thomas A. Raffin. (1991). Attenuation of LPS‐induced neutrophil thromboxane B₂ release and chemiluminescence. Journal of Cellular Physiology. 146(2). 264–269. 16 indexed citations

20.

Hoffmann, Hans, J. Robert Hatherill, Jeffrey Crowley, et al.. (1991). Early Post-Treatment with Pentoxifylline or Dibutyryl cAMP Attenuates Escherichia coli -induced Acute Lung Injury in Guinea Pigs. American Review of Respiratory Disease. 143(2). 289–293. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact